Trade Cidara Therapeutics, Inc. - CDTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2696 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 21.0202 |
| Open | 20.7202 |
| 1-Year Change | 2708% |
| Day's Range | 20.7202 - 21.7702 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 21.5602 | 1.0800 | 5.27% | 20.4802 | 21.8602 | 20.3402 |
| Jan 16, 2025 | 21.0202 | 1.0500 | 5.26% | 19.9702 | 21.6802 | 19.9702 |
| Jan 15, 2025 | 20.3902 | -0.0600 | -0.29% | 20.4502 | 21.0802 | 19.5602 |
| Jan 14, 2025 | 20.6602 | -0.3200 | -1.53% | 20.9802 | 22.0702 | 20.5302 |
| Jan 13, 2025 | 21.0802 | -2.1700 | -9.33% | 23.2502 | 23.6402 | 20.9702 |
| Jan 10, 2025 | 23.9602 | -0.0500 | -0.21% | 24.0102 | 24.6402 | 22.0602 |
| Jan 8, 2025 | 24.7702 | -1.2000 | -4.62% | 25.9702 | 26.1702 | 21.4802 |
| Jan 7, 2025 | 26.9002 | -0.0800 | -0.30% | 26.9802 | 27.5202 | 25.9702 |
| Jan 6, 2025 | 26.4602 | 0.4900 | 1.89% | 25.9702 | 26.7902 | 25.0202 |
| Jan 3, 2025 | 26.5902 | -0.5400 | -1.99% | 27.1302 | 27.4702 | 25.3702 |
| Jan 2, 2025 | 27.0502 | 1.0800 | 4.16% | 25.9702 | 28.2002 | 25.9702 |
| Dec 31, 2024 | 26.6302 | 1.2500 | 4.93% | 25.3802 | 27.2602 | 24.7202 |
| Dec 30, 2024 | 25.0502 | 1.5700 | 6.69% | 23.4802 | 25.2102 | 23.2302 |
| Dec 27, 2024 | 23.4102 | -0.0600 | -0.26% | 23.4702 | 24.0302 | 22.6802 |
| Dec 26, 2024 | 22.8902 | 0.2700 | 1.19% | 22.6202 | 23.2602 | 22.6202 |
| Dec 24, 2024 | 22.9902 | 0.4200 | 1.86% | 22.5702 | 24.2702 | 22.5702 |
| Dec 23, 2024 | 23.1702 | -0.0400 | -0.17% | 23.2102 | 23.9702 | 22.6202 |
| Dec 20, 2024 | 22.7702 | 0.5000 | 2.25% | 22.2702 | 23.3202 | 20.9702 |
| Dec 19, 2024 | 22.4402 | 1.8800 | 9.14% | 20.5602 | 23.4002 | 20.3202 |
| Dec 18, 2024 | 20.4702 | -1.7500 | -7.88% | 22.2202 | 22.2202 | 19.1702 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cidara Therapeutics, Inc. Company profile
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The Company's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cidara Therapeutics Inc revenues increased from $12.1M to $49.6M. Net loss applicable to common stockholders decreased 43% to $42.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 9% to $1.9M (expense), Interest income (expense).
| Industry: | Bio Therapeutic Drugs |
6310 Nancy Ridge Dr Ste 101
SAN DIEGO
CALIFORNIA 92121-3209
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com